Elsevier

Vaccine

Volume 33, Issue 6, 4 February 2015, Pages 812-818
Vaccine

Application of Bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2

https://doi.org/10.1016/j.vaccine.2014.12.003Get rights and content

Highlights

  • VP2 from several serotypes can be expressed on bluetongue virus DISA vaccine.

  • Exchange of VP2 from some serotypes on bluetongue virus DISA vaccine is not possible.

  • Chimeric VP2 of BTV1 and BTV16 is functional in vitro and in vivo.

  • BTV with chimeric VP2 is neutralized by sera against both parental serotypes.

  • BTV DISA vaccine with chimeric VP2 induces nAbs against both parental serotypes.

Abstract

Bluetongue is a disease of ruminants caused by the bluetongue virus (BTV). Bluetongue outbreaks can be controlled by vaccination, however, currently available vaccines have several drawbacks. Further, there are at least 26 BTV serotypes, with low cross protection. A next-generation vaccine based on live-attenuated BTV without expression of non-structural proteins NS3/NS3a, named Disabled Infectious Single Animal (DISA) vaccine, was recently developed for serotype 8 by exchange of the serotype determining outer capsid protein VP2. DISA vaccines are replicating vaccines but do not cause detectable viremia, and induce serotype specific protection. Here, we exchanged VP2 of laboratory strain BTV1 for VP2 of European serotypes 2, 4, 8 and 9 using reverse genetics, without observing large effects on virus growth. Exchange of VP2 from serotype 16 and 25 was however not possible. Therefore, chimeric VP2 proteins of BTV1 containing possible immunogenic regions of these serotypes were studied. BTV1, expressing 1/16 chimeric VP2 proteins was functional in virus replication in vitro and contained neutralizing epitopes of both serotype 1 and 16. For serotype 25 this approach failed. We combined VP2 exchange with the NS3/NS3a negative phenotype in BTV1 as previously described for serotype 8 DISA vaccine. DISA vaccine with 1/16 chimeric VP2 containing amino acid region 249–398 of serotype 16 raised antibodies in sheep neutralizing both BTV1 and BTV16. This suggests that DISA vaccine could be protective for both parental serotypes present in chimeric VP2. We here demonstrate the application of the BT DISA vaccine platform for several serotypes and further extend the application for serotypes that are unsuccessful in single VP2 exchange.

Introduction

Bluetongue (BT) is a notifiable disease of ruminants caused by the bluetongue virus (BTV) and is spread by Culicoides biting midges. BT is endemic in tropical regions, but is expanding to regions with a moderate climate due to emerging vector species [1], [2]. BT outbreaks can cause large economic losses due to diseased animals and trade restrictions [3], [4].

BTV (family Reoviridae, genus Orbivirus) has a ten-segmented (Seg-1–10), double stranded (ds) RNA genome. The non-enveloped virus particle contains a triple layered capsid of viral proteins VP2, 3, 5, and 7. VP2 is the most immunogenic and the major serotype determining protein, inducing neutralizing antibodies (nAbs) [5]. There are at least 26 BTV serotypes, defined by neutralizing antibodies and confirmed by VP2 phylogenetic analyses [6], [7]. In addition to the replication complex consisting of VP1, 4, and 6 [8], [9], [10], BTV expresses four non-structural (NS) proteins [11], [12], [13]. Although NS3/NS3a is important for virus release from infected cells [14], [15], [16], expression is not essential for virus replication in vitro [17], [18].

Control of BT outbreaks is hardly possible without vaccination [19]. Vaccination in African countries occurs with conventionally live-attenuated BT vaccines [20], but the safety of these vaccines is questionable [21], [22], [23]. Safe and effective inactivated BT vaccines have been developed [24], however, protection might not be long lasting, and annual re-vaccination is recommended. In Europe, BTV serotypes 1, 2, 4, 8, 9 and 16 are currently present [25].

Recently, we developed BT Disabled Infectious Single Animal (DISA) vaccines for serotype 8 [26], [45]. DISA vaccine 8 consists of the backbone of vaccine-related BTV6/net08 [27] without NS3/NS3a expression, and VP2 of serotype 8. DISA vaccine 8 is avirulent, replicates locally without causing detectable viremia, induces serotype specific protection against virulent BTV8, and enables the differentiation of infected from vaccinated animals (DIVA) based on NS3-directed antibodies.

Exchange of outer capsid proteins has been described for several BTV serotypes [28], [29], but is not possible for all 26 serotypes [30]. VP2 interacts with VP5 and VP7 and is involved in cell entry [31]. However, the regions involved in cell entry, and which are thus exposed to the outer part of the virion, as well as VP2 regions interacting with VP5 and VP7 have not been mapped. The VP2 sequence is highly variable between serotypes and there are only some conserved cysteine residues and two more conserved areas described [32]. Neutralizing epitopes are more prevalent in two regions in VP2, but are also scattered throughout the protein [33], [34], [35], [36]. A protein structure has been proposed for VP2 of the related African horse sickness virus (AHSV), and the outer tip domain of AHSV VP2 triskellions has been mapped to amino acid (AA) region 279–368 of BTV VP2 [37].

The BT DISA vaccine platform was here applied for BTV serotypes currently present in Europe by exchange of VP2, but rescue of virus with VP2 of serotype 16 was not possible. Therefore, chimeric VP2 genes encoding proposed immunogenic regions of BTV16 VP2 were expressed on BTV1 and BTV1 without NS3/NS3a expression. The serotype specific immunogenicity of both parental serotypes was examined in vitro and in vivo by neutralization assays and vaccination of sheep.

Section snippets

Cells and viruses

BSR cells (a clone of BHK-21 cells [38]) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen), containing 5% fetal bovine serum (FBS), 100 IU ml−1 Penicillin, 100 μg ml−1 Streptomycin and 2.5 μg ml−1 Amphotericin B.

BTV1 generated by reverse genetics (Genbank accession numbers FJ969719FJ969728) was used as virus backbone to rescue BTV1 derivatives as previously described [39], [40]. Seg-2 originating from strain BTV2 (JN255863), BTV4 (AJ585125), BTV8 (AM498052), BTV9 (AJ585130),

Exchange of entire VP2 in BTV of serotypes currently present in Europe

BTV1 with VP2 of serotype 2, 4, 8 or 9 was generated by use of reverse genetics. Exchange of single VP2 of proposed BTV serotype 25 (Toggenburg orbivirus) [41] did not result in viable virus (Table 2), whereas exchange of both VP2 and VP5 of serotype 25 was successful (not shown). For serotype 16, exchange of single VP2 (Table 2), or of both VP2 and VP5 did not result in virus rescue (not shown).

Exchange of VP2 was combined with Seg-10 deletion ΔC (NS3/NS3a knockout) to generate BTV1-based DISA

Discussion

Previously, we described the development of the BT Disabled Infectious Single Animal (DISA) vaccine for serotype 8 [26], [45]. Here, we investigated the broader application of this DISA vaccine platform for ‘European’ serotypes 2, 4, 8, 9 and 16 by exchange of entire VP2 in BTV1 without NS3/NS3a expression. DISA vaccine with VP2 of serotype 2, 4, 8 and 9 were generated and virus growth and plaque size were in most cases similar to BTV1 DISA vaccine. Exchange of VP2 of serotype 16 in the BTV1

Acknowledgements

This study was funded by the Dutch Ministry of Economic Affairs (CVI-project 1600020-01). We thank René van Gennip for fruitful discussions and Rob Moormann for critical reading of the manuscript. We also thank the CVI animal caretakers for excellent assistance and Phaedra Eblé for veterinary supervision of the animal experiment. We would also like to thank Carrie Batten for the generous gift of anti-BTV16 serum, Mieke Maris for assistance with neutralization assays and Aldo Dekker for support

References (45)

  • V. Chaignat et al.

    Toggenburg orbivirus, a new bluetongue virus: initial detection, first observations in field and experimental infection of goats and sheep

    Vet Microbiol

    (2009)
  • M.H. Jeggo et al.

    Role of neutralising antibody in passive immunity to bluetongue infection

    Res Vet Sci

    (1984)
  • M. Eschbaumer et al.

    Emergence of bluetongue virus serotype 6 in Europe – German field data and experimental infection of cattle

    Vet Microbiol

    (2010)
  • F. Feenstra et al.

    VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA

    Vaccine

    (2014)
  • B.V. Purse et al.

    Climate change and the recent emergence of bluetongue in Europe

    Nat Rev Microbiol

    (2005)
  • K. Hoogendam

    International study on the economic consequences of outbreaks of bluetongue serotype 8 in north-western Europe

    (2007)
  • W.J. Tabachnick et al.

    Culicoides variipennis and bluetongue disease. Research on arthropod-borne animal diseases for control and prevention in the year 2000

    Ann N Y Acad Sci

    (1996)
  • M.A. Hofmann et al.

    Genetic characterization of toggenburg orbivirus, a new bluetongue virus, from goats, Switzerland

    Emerg Infect Dis

    (2008)
  • S. Maan et al.

    Novel bluetongue virus serotype from Kuwait

    Emerg Infect Dis

    (2011)
  • T. Urakawa et al.

    Expression of largest RNA segment and synthesis of VP1 protein of bluetongue virus in insect cells by recombinant baculovirus: association of VP1 protein with RNA polymerase activity

    Nucleic Acids Res

    (1989)
  • N. Stauber et al.

    Bluetongue virus VP6 protein binds ATP and exhibits an RNA-dependent ATPase function and a helicase activity that catalyze the unwinding of double-stranded RNA substrates

    J Virol

    (1997)
  • G. Sutton et al.

    Bluetongue virus VP4 is an RNA-capping assembly line

    Nat Struct Mol Biol

    (2007)
  • Cited by (35)

    • Highly efficient vaccines for Bluetongue virus and a related Orbivirus based on reverse genetics

      2020, Current Opinion in Virology
      Citation Excerpt :

      However, unlike ECRA, DISA vaccines are capable of low-level replication leaving one the possibility of the reacquisition of NS3 type functions from the host or a concurrent virus infection. Nevertheless, vaccine studies with DISA vaccines have shown protection in vaccinated animals and an inability to replicate in the Culicoides vector, which would likely block animal transmission [22,23]. AHSV which is transmitted by biting midges similar to BTV causes severe disease in equids, with 95% mortality in naïve horses.

    • Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep

      2019, Vaccine
      Citation Excerpt :

      Related homogenous viruses in the same Reoviridae family were also successfully produced using the same plant expression platform [4]. Self-assembly of homogenous BT VLPs does not always occur [10], and it is necessary to identify the appropriate core-like particle backbone to facilitate the assembly of chimaeric VLPs in the development of multivalent BT VLP vaccines. In this study, genes encoding the selected capsid proteins from more than one serotype were individually cloned into the plant expression vector, pEAQ-HT, and homogenous BTV-8, chimaeric BTV-4 and chimaeric BTV-3 VLPs were successfully assembled and purified from N. benthamiana plants for target animal trials.

    View all citing articles on Scopus
    View full text